NCT03693430
STEP — semaglutide in obesity
Phase Phase 3
Status Completed
Indication Obesity
Enrollment 1,961
Last updated:Jul 15, 2026Source:ClinicalTrials.govVerified:NCT ID verified against public registryData provider:ClinicalTrials.gov API v2
Overview
- NCT ID
- NCT03693430
- Phase
- Phase 3
- Status
- Completed
- Indication
- Obesity
- Primary completion
- 3/1/2020
- Enrollment (planned/actual)
- 1,961
- Sponsor
- Novo Nordisk
- Peptide
- Semaglutide
Peptide under study
Semaglutide
GLP-1 receptor agonist · Approved